^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Soft Tissue Sarcoma
    Drug:Enweida (envafolimab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Tracon Pharmaceuticals Press Release
    Title:

    TRACON Pharmaceuticals Announces Fast Track Designation By The FDA For Envafolimab For The Treatment Of The Soft Tissue Sarcoma Subtypes Of UPS And MFS

    Published date:
    09/14/2022
    Excerpt:
    TRACON Pharmaceuticals...announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy.